Výsledky vyhledávání

Sagopilone (ZK-EPO, ZK 219477) for recurrent glioblastoma. A phase II multicenter trial by the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor Group

Autor: H. Wiesinger, Ulrich Bogdahn, Jacoline E C Bromberg, Alicia Tosoni, J.M.M. Gijtenbeek, Peter Hau, W.T.A. van der Graaf, Anouk Allgeier, Denis Lacombe, Marc Frenay, Mario Campone, Alba A. Brandes, Roger Stupp, Hwan Jung Yun, M. J. van den Bent, L. Breimer, Thierry Gorlia

Publikováno v: Annals of Oncology, 22, 2144-9
Annals of Oncology, 22, 9, pp. 2144-9
Annals of Oncology, vol. 22, no. 9, pp. 2144-2149
Annals of Oncology
Annals of Oncology, 22(9), 2144-2149. Elsevier Ltd.

Item does not contain fulltext BACKGROUND: Sagopilone (ZK 219477), a lipophylic and synthetic analog of epothilone B, that crosses the blood-brain barrier has demonstrated preclinical activity in glioma models. PATIENTS AND METHODS: Patients with fir

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aff761ff942a5427a762451d3bee2780
http://doc.rero.ch/record/291521/files/mdq729.pdf

Zobrazit plný text záznamu

Nuclear factor 1 activates the feline leukemia virus long terminal repeat but is posttranscriptionally down-regulated in leukemia cell lines

Autor: M. Plumb, James C. Neil, Meredith Stewart, Keith R. Willison, L Breimer, R. Fulton

Publikováno v: Journal of Virology. 65:1991-1999

A recombinant feline leukemia virus (FeLV) proviral clone (T17T-22) with a long terminal repeat (LTR) which differs from prototype FeLV by a point mutation within a conserved nuclear factor 1 (NF1)-binding motif in the LTR enhancer domain was found t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5564fd873de082e87aaacaaff267d84b
https://doi.org/10.1128/jvi.65.4.1991-1999.1991

Zobrazit plný text záznamu

Academia and industry - working together to fight cancer

Autor: L, Breimer

Publikováno v: IDrugs : the investigational drugs journal. 4(4)

Academic centers and the pharmaceutical industry are working well together to improve the treatment of cancer. New agents are being tested in the clinic, including monoclonal antibodies with little toxicity. Academics help industry by identifying new

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::b63fdbe86da1060f866a33a0be207697
https://pubmed.ncbi.nlm.nih.gov/16015475

Zobrazit plný text záznamu

Possible benefits of low molecular weight heparins

Autor: L Breimer

Publikováno v: BMJ (Clinical research ed.). 309(6960)

EDITOR, - Consideration of the main end points used in the studies included in A Leizorovicz and colleagues' meta-analysis of the possible merits of low molecular weight heparin1 illustrates certain difficulties in persuading the uninitiated of the v

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16ef41238e3810f0794a1e296adda365
https://pubmed.ncbi.nlm.nih.gov/7950705

Zobrazit plný text záznamu

Fraud

Autor: L. Breimer, L. Brown, A. Skinner, A. Gani, H. Hillman, J. Rymer

Publikováno v: BMJ. 317:1590-1590

Editor—Only one of the five papers on dealing with research misconduct in the United Kingdom (that by Riis) mentions the pharmaceutical industry and the national medicines regulatory agencies—and only as an aside.1 Licences for drugs are granted

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6ebf2bb43c5224d68e2c6dead76b5001
https://doi.org/10.1136/bmj.317.7172.1590

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Vyhledávací nástroje:

Upřesnit hledání